ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2026
Safe and Efficient Extracorporeal Photopheresis in Patients with Pre-Procedure Hematocrit below 26.
Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracorporeal photopheresis (ECP) is widely used for graft-versus-host disease (GVHD), but manufacturer recommendations suggest maintaining a pre-procedure hematocrit (Hct) above 27%. This study evaluates the safety and efficacy of ECP performed at lower Hct levels. Methods: We retrospectively analyzed 13 ECP procedures in three male patients with GVHD, comparing sessions performed at Hct < 26% to those at Hct > 27%. Procedural parameters, hemodynamic stability, and adverse events were assessed. Results: All procedures at Hct < 26% were successfully completed without adverse reactions, vascular access issues, or significant hemodynamic changes. Average procedure duration was 97 min at Hct < 26% and 95 min at Hct > 27%, showing no significant impact on efficiency. Conclusion: ECP at Hct < 26% is safe and effective, reducing the need for transfusion while maintaining procedural integrity. These findings challenge current Hct thresholds and support more flexible patient selection criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.